Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New vaccine aims to block HPV cancers beyond current shots

NCT ID NCT05985681

First seen Nov 01, 2025 · Last updated Jun 05, 2026 · Updated 35 times

Summary

This early-stage trial tests a new vaccine called RG1-VLP in 18 healthy women to see if it is safe and can trigger an immune response against HPV types not covered by current vaccines. HPV is a common infection that can cause certain cancers. The goal is to find the best dose and see if this vaccine could offer broader protection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS-RELATED CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    WITHDRAWN

    Baltimore, Maryland, 21287, United States

  • Medical University Vienna

    NOT_YET_RECRUITING

    Vienna, A-1090, Austria

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Staten Island University Hospital

    WITHDRAWN

    Staten Island, New York, 10305, United States

  • University of Alabama at Birmingham Cancer Center

    WITHDRAWN

    Birmingham, Alabama, 35233, United States

  • University of Wisconsin Carbone Cancer Center - University Hospital

    RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

human papillomavirus-related squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.